XMU-MP-2 is a BRK inhibitor with significant inhibitory activity on BRK-positive cells. XMU-MP-2 inhibits oncogenic BRK-driven tumor growth in a mouse xenograft model. XMU-MP-2 also synergizes with HER2 inhibitors or endoplasmic reticulum (ER) blockade to exert antiproliferative activity.
References:
[1]. Jiang J, et al. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors. Cancer Res. 2017 Jan 1;77(1):175-186.
















